好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A hospital’s perspective: economic evaluation of hospitalization vs rapid outpatient evaluation for TIA and minor strokes.
Cerebrovascular Disease and Interventional Neurology
P3 - Poster Session 3 (5:30 PM-6:30 PM)
3-010
To demonstrate the cost-effectiveness  of a rapid outpatient evaluation for patient who present to the emergency department with TIA and minor strokes 

Patients presenting to emergency departments (ED) with TIA and minor strokes (TIAMS) are often admitted for expedited evaluation, though outpatient care models have been proposed. We piloted a rapid outpatient evaluation protocol for patients presenting with TIAMS within 24 hours of ED discharge. We hypothesized that this approach would reduce hospital costs and length of stay (LOS).

This analysis looked at patients presenting to our institution’s ED with TIAMS (NIHSS<5) in calendar year 2017. We compared hospitalization LOS, costs and expected revenues between admitted patients and those referred for rapid outpatient evaluation. Patients eligible for outpatient evaluation were without disabling deficits, recurrent symptoms, new-onset atrial fibrillation, prior carotid imaging with >50% stenosis, and not receiving thrombolysis. Disabling deficits were defined as new gait impairments, significant motor weakness, hemianopia, dysphagia or severe aphasia. Cost data was obtained from our finance department and expected revenue was estimated using Medicare reimbursement data, assuming Medicare-Fee for Service as the primary payer for all patients.

We identified 92 patients referred to our rapid outpatient clinic and 90 admitted patients (mean NIHSS 0.8 vs 1.8 respectively). In comparison to patients who were admitted, patients referred to outpatient evaluation had shorter hospital stays, lower total hospitalization costs, and decreased net-losses after accounting for expected revenue (Table). Only one patient in the outpatient cohort was readmitted for further management. Overall, the pilot cohort averted approximately 138 bed-days and $950,000 in hospitalization costs.   

For patients who presented to our ED with TIAMS without disabling deficits, rapid outpatient evaluation reduced hospital LOS and total costs. Further research is needed to incorporate costs to payers and patients.

Authors/Disclosures
Steven D. Shapiro, MD (Cooperman Barnabas Medical Center)
PRESENTER
Dr. Shapiro has nothing to disclose.
Jorge M. Luna No disclosure on file
Rachel P. Mehendale, MD (University of Chicago) Dr. Mehendale has nothing to disclose.
Babak Navi, MD (Weill Cornell Medical College) Dr. Navi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Navi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MindRhythm Inc. Dr. Navi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for multiple medicolegal firms.
Benjamin R. Kummer, MD, FAAN Dr. Kummer has received personal compensation in the range of $0-$499 for serving as a Consultant for AlphaSights. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Syapse. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuraHealth. Dr. Kummer has received personal compensation in the range of $0-$499 for serving as a Consultant for RONIN. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Kummer has received personal compensation in the range of $0-$499 for serving as a Consultant for GLG. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Petauri Kinect. Dr. Kummer has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for 好色先生 . Dr. Kummer has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JMIR. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Seminars in Neurology. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Yoeli Gottlieb Etra LLP. Dr. Kummer has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for The Ashley Law Firm. Dr. Kummer has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Burns White Attorneys at Law. Dr. Kummer has stock in Syntrillo. The institution of Dr. Kummer has received research support from Icahn School of Medicine at Mount Sinai. Dr. Kummer has a non-compensated relationship as a Vice Chair Telehealth Subcommitte with 好色先生 that is relevant to AAN interests or activities. Dr. Kummer has a non-compensated relationship as a Vice Chair Quality Informatics Subcommittee with 好色先生 that is relevant to AAN interests or activities.
Sara K. Rostanski, MD (NYU School of Medicine) Dr. Rostanski has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Individual law firms.
No disclosure on file
No disclosure on file
Bernard S. Chang, MD (Harvard Medical School) Dr. Chang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Medical Association. Dr. Chang has received publishing royalties from a publication relating to health care.
Eliza C. Miller, MD (University of Pittsburgh) Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for medical malpractice cases. The institution of Dr. Miller has received research support from National Institutes of Health. Dr. Miller has a non-compensated relationship as a member of ASA Advisory Council with American Heart Association/American Stroke Association that is relevant to AAN interests or activities.
Mitchell S. Elkind, MD, MS, FAAN Dr. Elkind has received personal compensation for serving as an employee of American Heart Association. Dr. Elkind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atria Academy.
Joshua Z. Willey, MD, FAAN (Columbia University) Dr. Willey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Edwards Scientific. Dr. Willey has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for RECARDIO. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbott. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainQ. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of the American College of Cardiology. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Uptodate. The institution of Dr. Willey has received research support from NIH. Dr. Willey has received personal compensation in the range of $500-$4,999 for serving as a Review chapter author, MKSAP 16-20 with American College of Physicians.